About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%) Stock is Up 0.25 (2.20%)
Data as of 05/25/18 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $11.62 with a 52 week high of $14.76 and a 52 week low of $7.78.

Recent News

Natera Reports First Quarter 2018 Financial Results - 05/08/18
SAN CARLOS, Calif., May 8, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2018, and pro... More»
Natera Inc. Announces First Quarter 2018 Earnings Conference Call - 05/01/18
SAN CARLOS, Calif., May 1, 2018 /PRNewswire/ -- Natera, (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its first quarter ended March 31, 2018, a... More»
Natera to Present Successful Results at AACR from Bladder and Colon Cancer Studies - 04/13/18
Performance Data for Treatment Monitoring, Recurrence Monitoring, and Staging at Diagnosis SAN CARLOS, Calif., April 13, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-fr... More»
Natera To Present New Data at ACMG Annual Meeting - 04/10/18
Study results demonstrate value of SNP-based non-invasive prenatal testing, expanded carrier screening, and embryo and miscarriage tissue testing across various genetic conditions SAN CARLOS, Calif., April 10, 2018 /PRNewswire/ -- Natera (NASDAQ... More»
Natera Appoints Paul R. Billings, M.D., Ph.D., as Chief Medical Officer - 04/09/18
Leading authority on genomics and diagnostics in medical practice will help Natera's efforts in advancing individualized genomic medicine SAN CARLOS, Calif., April 9, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic t... More»

Upcoming Events

There are currently no events scheduled.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Shareholder Tools